<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34313819</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD-ALS spectrum.</ArticleTitle><Pagination><StartPage>1522</StartPage><EndPage>1529</EndPage><MedlinePgn>1522-1529</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10714-3</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The 'Frontotemporal dementia-Amyotrophic lateral sclerosis Spectrum' (FAS) encompasses different phenotypes, including cognitive disorders (frontotemporal dementia, FTD) and/or motor impairments (amyotrophic lateral sclerosis, ALS). The aim of this study was to apprehend the specific uses of neurofilaments light chain (NfL) and phosphorylated neurofilaments heavy chain (pNfH) in a context of FAS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">First, NfL and pNfH were measured in 39 paired cerebrospinal fluid (CSF) and plasma samples of FAS and primary psychiatric disorders (PPD) patients, considered as controls. Secondly, additional plasma samples were included to examine a larger cohort of 81 samples composed of symptomatic FAS and PPD patients, presymptomatic and non-carrier relatives individuals. The measures were performed using Simoa technology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was a positive correlation between CSF and plasma values for NfL (p&#x2009;&lt;&#x2009;0.0001) and for pNfH (p&#x2009;=&#x2009;0.0036). NfL values were higher for all phenotypes of symptomatic FAS patients compared to PPD patients (p&#x2009;=&#x2009;0.0016 in CSF; p&#x2009;=&#x2009;0.0003 in plasma). On the contrary, pNfH values were solely increased in FAS patients exhibiting motor impairment. Unlike symptomatic FAS patients, presymptomatic cases had comparable concentrations with non-carrier individuals.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">NfL, but not pNfH, appeared to be useful in a context of differential diagnosis between FTD and psychiatric patients. Nevertheless, pNfH seem more specific for the diagnosis and follow-up of motor impairments. In each specific indication, measures in CSF and plasma will provide identical interpretations.</AbstractText><CopyrightInformation>&#xa9; 2021. Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Escal</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Neurobiology and Neurogenetics, Department of Biochemistry and Molecular Biology, Lyon University Hospital, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BIORAN Team, Lyon Neuroscience Research Center, CNRS UMR 5292, INSERM U1028, Lyon 1 University, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fourier</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3995-0500</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurobiology and Neurogenetics, Department of Biochemistry and Molecular Biology, Lyon University Hospital, Bron, France. anthony.fourier@chu-lyon.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BIORAN Team, Lyon Neuroscience Research Center, CNRS UMR 5292, INSERM U1028, Lyon 1 University, Bron, France. anthony.fourier@chu-lyon.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Formaglio</LastName><ForeName>Mait&#xe9;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurocognition and Neuro-Ophthalmology Department, Lyon University Hospital, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Memory Resources and Research, Lyon University Hospital, Lyon 1 University, Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmer</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>BIORAN Team, Lyon Neuroscience Research Center, CNRS UMR 5292, INSERM U1028, Lyon 1 University, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Emilien</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Reference Center of ALS of Lyon, Lyon University Hospital, Lyon 1 University, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NeuroMyoG&#xe8;ne Institute, CNRS UMR 5310, INSERM U1217, Lyon 1 University, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mollion</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurocognition and Neuro-Ophthalmology Department, Lyon University Hospital, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Memory Resources and Research, Lyon University Hospital, Lyon 1 University, Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bost</LastName><ForeName>Muriel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Neurobiology and Neurogenetics, Department of Biochemistry and Molecular Biology, Lyon University Hospital, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herrmann</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Aging Psychiatry, Hospital Le Vinatier, Bron, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollagnon-Roman</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Predictive Medicine of Neurological and Neurodegenerative Diseases, Lyon University Hospital, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Quadrio</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory of Neurobiology and Neurogenetics, Department of Biochemistry and Molecular Biology, Lyon University Hospital, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BIORAN Team, Lyon Neuroscience Research Center, CNRS UMR 5292, INSERM U1028, Lyon 1 University, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Memory Resources and Research, Lyon University Hospital, Lyon 1 University, Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Dorey</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Aging Psychiatry, Hospital Le Vinatier, Bron, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain Dynamics and Cognition Team, Lyon Neuroscience Research Center, CNRS UMR 5292, INSERM U1028, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CSRL09</GrantID><Agency>H&#xf4;pital Le Vinatier France</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Blood biomarker</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">pNfH</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>27</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34313819</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10714-3</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10714-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sivasathiaseelan H, Marshall CR, Agustus JL, Benhamou E, Bond RL, Rohrer JD et al (2019) Frontotemporal dementia: a clinical review. Semin Neurol 39:251&#x2013;263. https://doi.org/10.1055/s-0039-1683379</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1683379</ArticleId><ArticleId IdType="pubmed">30925617</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377:162&#x2013;172. https://doi.org/10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva D, Hsieh S, Caga J, Leslie FVC, Kiernan MC, Hodges JR et al (2016) Motor function and behaviour across the ALS-FTD spectrum. Acta Neurol Scand 133:367&#x2013;372. https://doi.org/10.1111/ane.12471</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12471</ArticleId><ArticleId IdType="pubmed">26223148</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J et al (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134:2456&#x2013;2477. https://doi.org/10.1093/brain/awr179</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId><ArticleId IdType="pmc">3170532</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293&#x2013;299. https://doi.org/10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J (2019) Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener 20:303&#x2013;309. https://doi.org/10.1080/21678421.2019.1587634</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1587634</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Kantarci K (2020) Imaging biomarkers for neurodegeneration in presymptomatic familial frontotemporal lobar degeneration. Front Neurol. https://doi.org/10.3389/fneur.2020.00080</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00080</ArticleId><ArticleId IdType="pubmed">33732201</ArticleId><ArticleId IdType="pmc">7786250</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuer HW, Wang P, Rascovsky K, Wolf A, Appleby B, Bove J et al (2020) Comparison of sporadic and familial behavioral variant frontotemporal dementia (FTD) in a North American cohort. Alzheimer&#x2019;s Dement 16:60&#x2013;70. https://doi.org/10.1002/alz.12046</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari A (2019) ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 13:1310. https://doi.org/10.3389/fnins.2019.01310</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId><ArticleId IdType="pmc">6909825</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley JD, Khan BK, Murthy NK, Miller BL, Rankin KP (2011) The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. J Clin Psychiatry 72:126&#x2013;133. https://doi.org/10.4088/JCP.10m06382oli</Citation><ArticleIdList><ArticleId IdType="doi">10.4088/JCP.10m06382oli</ArticleId><ArticleId IdType="pubmed">21382304</ArticleId><ArticleId IdType="pmc">3076589</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinagawa S, Catindig JA, Block NR, Miller BL, Rankin KP (2016) When a little knowledge can be dangerous: false-positive diagnosis of behavioral variant frontotemporal dementia among community clinicians. Dement Geriatr Cogn Disord 41:99&#x2013;108. https://doi.org/10.1159/000438454</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000438454</ArticleId><ArticleId IdType="pubmed">26741499</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O (2000) Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 57:109&#x2013;113. https://doi.org/10.1001/archneur.57.1.109</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.1.109</ArticleId><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea TB, Chan WK-H (2008) Regulation of neurofilament dynamics by phosphorylation. Eur J Neurosci 27:1893&#x2013;1901. https://doi.org/10.1111/j.1460-9568.2008.06165.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06165.x</ArticleId><ArticleId IdType="pubmed">18412610</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan A, Rao MV, Nixon RA (2017) Neurofilaments and neurofilament proteins in health and disease. Cold Spring Harb Perspect Biol. https://doi.org/10.1101/cshperspect.a018309</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a018309</ArticleId><ArticleId IdType="pubmed">28373358</ArticleId><ArticleId IdType="pmc">5378049</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577&#x2013;589. https://doi.org/10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkels&#xf8; C (1996) Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 67:2013&#x2013;2018. https://doi.org/10.1046/j.1471-4159.1996.67052013.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1996.67052013.x</ArticleId><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Palermo G, Mazzucchi S, Della Vecchia A, Siciliano G, Bonuccelli U, Azuar C et al (2020) Different clinical contexts of use of blood neurofilament light chain protein in the spectrum of neurodegenerative diseases. Mol Neurobiol 57:4667&#x2013;4691. https://doi.org/10.1007/s12035-020-02035-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02035-9</ArticleId><ArticleId IdType="pubmed">32772223</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R (2011) Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 117:528&#x2013;537. https://doi.org/10.1111/j.1471-4159.2011.07224.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07224.x</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId><ArticleId IdType="pmc">3076545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon BA (2020) Neurofilaments in disease: what do we know? Curr Opin Neurobiol 61:105&#x2013;115. https://doi.org/10.1016/j.conb.2020.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2020.02.001</ArticleId><ArticleId IdType="pubmed">32151970</ArticleId><ArticleId IdType="pmc">7198337</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3:623&#x2013;636. https://doi.org/10.1002/acn3.325</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.325</ArticleId><ArticleId IdType="pubmed">27606344</ArticleId><ArticleId IdType="pmc">4999594</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM et al (2019) Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Front Degener 20:538&#x2013;548. https://doi.org/10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J et al (2017) Amyotrophic lateral sclerosis-frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Front Degener 18:153&#x2013;174. https://doi.org/10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association (2015) Diagnostic and statistical manual of mental disorders, 5th edn. https://doi.org/10.1176/appi.books.9780890425596</Citation></Reference><Reference><Citation>MacLeod R, Tibben A, Frontali M, Evers-Kiebooms G, Jones A, Martinez-Descales A et al (2013) Recommendations for the predictive genetic test in Huntington&#x2019;s disease. Clin Genet 83:221&#x2013;231. https://doi.org/10.1111/j.1399-0004.2012.01900.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.2012.01900.x</ArticleId><ArticleId IdType="pubmed">22642570</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K et al (2019) Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. J Psychiatr Res 113:137&#x2013;140. https://doi.org/10.1016/j.jpsychires.2019.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2019.03.019</ArticleId><ArticleId IdType="pubmed">30953863</ArticleId></ArticleIdList></Reference><Reference><Citation>Goossens J, Bjerke M, Van Mossevelde S, Van den Bossche T, Goeman J, De Vil B et al (2018) Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimer&#x2019;s Res Therapy 10:31. https://doi.org/10.1186/s13195-018-0364-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-018-0364-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo P, Le Ber I, Camuzat A, Clot F, Naccache L, Lamari F et al (2014) Extensive white matter involvement in patients with frontotemporal lobar degeneration: think progranulin. JAMA Neurol 71:1562&#x2013;1566. https://doi.org/10.1001/jamaneurol.2014.1316</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1316</ArticleId><ArticleId IdType="pubmed">25317628</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Boeve BF, Weigand SD, Senjem ML, Gunter JL, Baker MC et al (2015) Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images. Eur J Neurol 22:745&#x2013;752. https://doi.org/10.1111/ene.12675</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12675</ArticleId><ArticleId IdType="pubmed">25683866</ArticleId><ArticleId IdType="pmc">4390434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Pujol-Calder&#xf3;n F, Barro C, Stransky E, Blennow K, Michalak Z et al (2019) Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clin Chem Lab Med 57:1556&#x2013;1564. https://doi.org/10.1515/cclm-2019-0015</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2019-0015</ArticleId><ArticleId IdType="pubmed">31251725</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijnenburg YA, Janssen JC, Schoonenboom NS, Petzold A, Mulder C, Stigbrand T et al (2007) CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer&#x2019;s disease and controls. Dement Geriatr Cogn Disord 23:225&#x2013;230. https://doi.org/10.1159/000099473</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000099473</ArticleId><ArticleId IdType="pubmed">17290105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Daughrity LM, Heckman MG, Diehl NN, Wuu J, Miller TM et al (2017) Phosphorylated neurofilament heavy chain: a biomarker of survival for C9ORF 72-associated amyotrophic lateral sclerosis. Ann Neurol 82:139&#x2013;146. https://doi.org/10.1002/ana.24980</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24980</ArticleId><ArticleId IdType="pubmed">28628244</ArticleId><ArticleId IdType="pmc">5676468</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, Claeys KG, Herbst V, Brix B et al (2018) Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 89:367&#x2013;373. https://doi.org/10.1136/jnnp-2017-316605</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316605</ArticleId><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Shen D, Tai H, Cui L (2016) Neurofilaments in CSF as diagnostic biomarkers in motor neuron disease: a meta-analysis. Front Aging Neurosci 8:290. https://doi.org/10.3389/fnagi.2016.00290</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2016.00290</ArticleId><ArticleId IdType="pubmed">27965574</ArticleId><ArticleId IdType="pmc">5126108</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P (2019) Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol 9:1167. https://doi.org/10.3389/fneur.2018.01167</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId><ArticleId IdType="pmc">6345692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C et al (2016) Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry 87:1270&#x2013;1272. https://doi.org/10.1136/jnnp-2015-312972</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-312972</ArticleId><ArticleId IdType="pubmed">27188986</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiutori R, Aarum J, Zubiri I, Bremang M, Jung S, Sheer D et al (2018) The proteome of neurofilament-containing protein aggregates in blood. Biochem Biophys Rep 14:168&#x2013;177. https://doi.org/10.1016/j.bbrep.2018.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2018.04.010</ArticleId><ArticleId IdType="pubmed">29872749</ArticleId><ArticleId IdType="pmc">5986704</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafson AR, Durham HD, Julien JP, Kuhle J, Leppert D, Nixon RA et al (2020) Neurofilaments: neurobiological foundations for biomarker applications. Brain 143:1975&#x2013;1998. https://doi.org/10.1093/brain/awaa098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa098</ArticleId><ArticleId IdType="pubmed">32408345</ArticleId><ArticleId IdType="pmc">7363489</ArticleId></ArticleIdList></Reference><Reference><Citation>Barro C, Benkert P, Disanto G, Tsagkas C, Amann M, Naegelin Y et al (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141:2382&#x2013;2391. https://doi.org/10.1093/brain/awy154</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy154</ArticleId><ArticleId IdType="pubmed">29860296</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Oeckl P, Huss A, M&#xfc;ller K, Volk AE, Kuhle J et al (2016) Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol 79:152&#x2013;158. https://doi.org/10.1002/ana.24552</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24552</ArticleId><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, Bonetto V, Sorar&#xf9; G, Martinelli I, Parchi P, Liguori R et al (2020) Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol Neurodegeneration 15:58. https://doi.org/10.1186/s13024-020-00406-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00406-3</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>